1. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Issue 1 (January 2022) Authors: Verma, Subodh; Dhingra, Nitish K; Butler, Javed; Anker, Stefan D; Ferreira, Joao Pedro; Filippatos, Gerasimos; Januzzi, James L; Lam, Carolyn S P; Sattar, Naveed; Peil, Barbara; Nordaby, Matias; Brueckmann, Martina; Pocock, Stuart J; Zannad, Faiez; Packer, Milton; Packer, M; Anker, S; Butler, J; ... Journal: Lancet Issue: Volume 10:Issue 1(2022) Page Start: 35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P242Cardiovascular vigor derived from exercise capacity and heart rate recovery is a strong predictor of long-term survival in older adults. (28th August 2018) Authors: Sydo, N; Sydo, T; Murphy, J G; Merkely, B; Lopez-Jimenez, F; Allison, T G Journal: European heart journal Issue: Volume 39(2018)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗